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Abstract
Background Pain in cancer patients is often related to onco-
logic therapies and diagnostic procedures. The placement of
fully implantable venous access systems is a very common
procedure in oncology patients. Local anaesthesia is the meth-
od most commonly used to overcome pain related to this sur-
gical procedure, but the local anaesthetic may be unable to
completely eradicate all pain. This study investigates the ef-
fectiveness and safety of fentanyl buccal tablet (FBT), admin-
istered by OraVescent® technology, in reducing procedural
pain related to the placement of indwelling central venous
access systems (Ports) in opioid-naïve cancer patients.
Methods Inpatients who required an indwelling vascular ac-
cess (Port) were preoperatively assessed with a self-
assessment questionnaire on anxiety and pain. A 100 μg
FBTwas administered 10 min before preparation of the oper-
ating field. A self-assessment scale for pain experienced dur-
ing the procedure was administered at the end of the proce-
dure. Vital signs and the presence of any side effects or
bothersome symptoms were monitored during the procedure,
at the end, and 4 h later.
Results From October 2012 to June 2014, 65 patients were
enrolled in the study. A total of 61 (93.9 %) patients perceived
no or a little pain during the procedure. Four patients (6.2 %)
reported a lot of pain. No patient reported very severe pain.
This data is significant in terms of the lower than expected
presence of pain (Fisher test p = 0.0018) as assessed in our
previous experience without procedural analgesia. The most
common side effects of FBTwas drowsiness, experienced by
28 patients at the end of the procedure (43.1 %), significantly
reduced (p < 0.01) to 8 patients after 4 h (12.5 %). Nausea was
present in 6 cases at the end of the procedure (9.2 %) and in 7
cases 4 h later (10.9 %). Vomiting was present in 3 cases at the
end (4.7 %) and in 2 other patients after 4 h (7.8 %). No
significant change of vital parameters was observed between
the baseline and the subsequent measurements in all patients
studied.
Conclusions The significant improvement in the number of
patients experiencing little or no pain, accompanied by a lower
number of non-severe side effects, suggests that FBT is a
valid, practical and safe method of procedural analgesia. It
will be necessary to perform further studies, taking into ac-
count the need for standard antiemetic pre-medication to min-
imise the incidence of nausea and vomiting.
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Introduction
During the course of their illness, cancer patients often expe-
rience pain that can be proportionately greater in the more
advanced stages of the disease. Of the various types of pain
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perceived, one particular form is procedural pain. Invasive
endoscopic, radiological and surgical diagnostic procedures
are mandatory steps in the diagnosis and therapy and can be
associated with pain that affects the patient’s quality of life [1].
The recommendation to prepare treatment protocols in order
to eliminate procedural pain has been expressed in well-
known guidelines [2]. The need to implement protocols to
achieve this aim is considered to be particularly important
when procedures involve cancer patients [3]. However, these
recommendations are frequently overlooked and procedural
pain is often not treated adequately [4]. In specific clinical
fields, such as paediatrics, the need to improve prevention
and treatment of procedural pain has recently encouraged re-
search in this care problem [5, 6]. For digestive endoscopy,
there are guidelines written by the major scientific societies
which recommend the gold standards, the best procedures and
the necessary training for medical professionals [7]. However,
there are no recent articles on procedural pain in the adult
oncology patient. The reason for this lies not only in the lim-
ited awareness about this topic of healthcare professionals, but
also in the objective difficulties that can be present in the
administration of procedural sedation and analgesia. The
placement of central venous catheters in cancer patients before
they start chemotherapy (CT) is a common procedure [8, 9],
and central venous access is usually obtained by catheteriza-
tion of the superior vena cava. The high blood flow and large
calibre of this blood vessel alone are able to neutralise the
phlebotic effect of continuous infusions of solutions and che-
motherapy and to allow the placement of venous catheters for
long periods [10]. In short, central venous accesses can be
classified as external catheters or fully implantable systems.
The latter are constituted by a reservoir (Port) connected to a
venous catheter whose tip is either open or closed by a valve.
The catheter is usually positioned in the vein using a percuta-
neous technique. An incision is made in the skin and the Port
is placed inside a pocket of subcutaneous tissue in the
subclavicular area, on the same side of the venipuncture site.
The connection between the catheter and the Port is performed
by tunnelling the catheter from the venipuncture site to the
subcutaneous pocket. Unlike external systems, implantable
systems preserve body image and are therefore better accepted
by patients from a cosmetic and psychological point of view.
In addition, they present the advantage of minimal interfer-
ence with daily living activities and make it possible, between
treatments, to maintain normal personal hygiene (e.g. baths
and showers). The positioning of a fully implantable venous
access system therefore constitutes a minor surgical proce-
dure, performed by a team including a surgeon or an anaes-
thesiologist who is optionally assisted by a second, and a
nurse. Local anaesthesia is the method most commonly used
to overcome pain related to the venipuncture, skin incision,
passage of the tunneller for the catheter and the detachment of
the subcutaneous tissue required to house the Port. This makes
it possible to have a cooperative patient during the vein iden-
tification and catheter introduction phases, which are facilitat-
ed by breathing and apnoea as ordered by the physician
performing the procedure. However, difficulties regarding
pain-related fear are often experienced during the injection
of the local anaesthetic and difficulties in positioning the im-
plants related to the pain caused by manoeuvres that cannot
always be perfectly controlled by local anaesthetic infiltration
(such as the catheter tunnelling phase). This entails reduced
patient cooperation and greater procedure-related stress. The
local anaesthetic may be unable to completely abolish all pain,
as its infiltration can itself cause severe burning before the
induction of anaesthesia, as well as the pain stimulus caused
in the pectoral muscle fascia during detachment. As regards
the central venous incannulation procedure for the positioning
of the Port, patients often present compromised peripheral
veins, making it difficult to identify a peripheral vein for the
administration of the procedural sedation and analgesia. In
other cases, the patient’s fear of the pain related to the veni-
puncture is another limiting factor. However, the intravenous
route is the route of election because of its rapid effect and the
possibility of using drugs with a short half-life, both essential
characteristics for ambulatory day hospital procedures with a
mean duration of 30–40 min, such as those for central venous
incannulation. Conventional oral drugs such as benzodiaze-
pines and short-release opioids have a latency of more than
30 min and duration of action of between 4 and 8 h, and
therefore, their characteristics are not ideal for use in the pro-
cedure in question. One potent opioid frequently used for
procedural sedation and analgesia is fentanyl. This opioid is
100 times more potent than morphine and is highly lipophilic
and therefore crosses the blood-brain barrier rapidly. These
characteristics have made it one of the most common drugs
used in modern surgical anaesthesia and it has also been ex-
tensively used in other clinical settings. It has been recognised
as being efficacious and manageable in radiological procedur-
al sedation and analgesia, where it is usually used at a dose of
1 μg/kg i.v. either alone or in combination with midazolam
[11, 12]. It has also been used with similarly demonstrated
efficacy and manageability when administered intravenously
at doses of between 1 and 2 μg/kg in the treatment of pre-
hospital pain management [13]. It has also recently been used
to treat procedural pain associated with venipuncture [14].
Description of the investigational medicinal product
For some years now, fentanyl has been available as a
transmucosal formulation. This method of administration
was devised to treat breakthrough cancer pain, i.e. the acute
and sudden pain that presents over background pain in pa-
tients on long-term opioid therapy. It has already been used
to produce procedural sedation and analgesia in cancer
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patients eligible for radiotherapy [15]. Fentanyl buccal tablet
(FBT) is a more recent formulation of transmucosal fentanyl
citrate. It uses OraVescent® technology to further increase the
rate and extent of absorption of fentanyl provided by its pre-
decessor compound, oral transmucosal fentanyl citrate
(OTFC). It improves dissolution and passage of the drug into
the circulation by selectively modifying the local pH and per-
meability at the mucosal wall. An initial decrease in pH pro-
motes the action of the soluble, ionised, hydrophilic form of
fentanyl, while a subsequent, gradual increase in pH promotes
the more absorbable, nonionized, lipophilic form. Fentanyl is
absorbed immediately after the administration of the tablet
with 65 % bioavailability, making it possible to induce rapid
analgesia after 5 to 15 min, with a peak in the effects within
2 h and a half-life that does not exceed 4 h. One 100-μg tablet
therefore releases a dose equivalent to 65 μg administered
intravenously [16, 17]. The drug has been approved for use
in patients pre-treated with daily opioid doses equal to 60 mg
of oral morphine sulphate. The aim of this is to minimise the
opioid side effects such as nausea, vomiting, drowsiness, pru-
ritus, mild hypotension and respiratory depression. Given its
characteristics, this formulation of fentanyl appeared to us to
be ideal for producing basic procedural analgesia prior to the
administration of local anaesthesia in Port-positioning candi-
dates. The buccal transmucosal administration route does not
require the use of a peripheral venous access and it is similar,
in terms of analgesic efficacy and latency, to an intravenous
injection, which is the most common route of administration
of the procedural analgesics indicated previously.
Aim of the study
The primary aim of the study was to evaluate FBT’s capacity
to reduce procedural pain related to the placement of an in-
dwelling central venous access system (Ports) in opioid-naïve
cancer patients.
The study’s secondary objectives were (i) to evaluate the
safety of FBTadministration in opioid-naïve patients in a hos-
pital setting and (ii) to evaluate the interference of pain-related
anxiety and fear experienced by patients before the procedure
in terms of their perception of pain.
Study design
From October 2012 till June 2014, all consecutive inpatient
candidates for indwelling vascular access (Port) positioning
for the administration of chemotherapy for histologically di-
agnosed cancer were assessed for eligibility. Before entering
the operating theatre (study time = T0), those patients whomet
the inclusion and exclusion criteria and had given their in-
formed consent to participate in the above study were given
a self-assessment questionnaire on anxiety (State-Trait Anxi-
ety Inventory Y-1 form) [18] and pain expectation; replies
were on a 4-point Likert scale: ‘not at all’, ‘a little’, ‘quite a
lot’ or ‘extremely painful’. Patients with a history of
anaesthesia-related nausea were treated with one
metoclopramide tablet 60 min before the procedure. Patients
received one buccal tablet of FBT. 100 μg 10 min before the
preparation of the operating field, and at the same time, their
vital parameters were monitored (respiratory rate, blood pres-
sure and peripheral arterial oxygenation). Self-assessment
scales for the pain experienced during the procedure and a
Visual Numeric Rating Scale 0–10 (VNRS 0–10) were admin-
istered at the end of the procedure (study time = T1). Vital
parameters weremonitored throughout the procedure. Patients
presenting pain that was self-assessed as significant during the
procedure (a lot of pain or extremely painful VNRS ≥5) were
provided with rescue therapy of one ampoule containing
30 mg of ketorolac for sub-lingual administration or tramadol
20 drops for patients with a positive history of reactions to
NSAIDs and ASA. Before the patients were sent to the Radi-
ology department for a follow-up chest X-ray, the physician
performing the procedure checked their vital signs and the
presence of any side effects or bothersome symptoms (T1).
A further closure assessment with the monitoring of vital pa-
rameters, side effects and bothersome symptoms was per-
formed 4 h after the Port implantation (study time = T2). A
pure opioid antagonist (naxolone) was readily available for
use throughout the procedure period to control any severe side
effects related to FBT administration.
Inclusion criteria
The inclusion criteria are as follows:
(1) Patients aged over 18 years.
(2) Histologically confirmed cancer diagnosis.
(3) Indication for the placement of the indwelling central
venous catheter connected to the subcutaneous Port as
an inpatient.
(4) Unimpaired cognitive capacity.
(5) Written informed consent.
Exclusion criteria
The exclusion criteria are as follows:
(1) Xerostomy or any other condition that does not make it
possible to take effervescent tablets.
(2) Patients already being treated with opioids for chronic
cancer pain.
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(3) A documented history of significant nausea and
vomiting related to the administration of opioids.
(4) A history of intolerance to intravenous fentanyl or FBT.
(5) Severe or moderate chronic respiratory insufficiency.
(6) Patients with renal or hepatic function impairment.
Statistical considerations
Central venous catheterization is a common procedure consid-
ered to be at risk in terms of pain, anxiety and discomfort [19].
However, there is no data available in literature on the preva-
lence of pain during the placement of an indwelling venous
system or Port. In 2010 and 2011, a total of 1152 Ports were
positioned in the Anaesthesiology and Intensive Care Unit of
this Institute. The pain perceived by patients during the pro-
cedure was routinely assessed using a 4-point Likert scale and
VNRS 0–10. The pain was judged as being no pain in 242
(21 %) patients, a little pain in 760 (66 %) patients, a lot of
pain in 92 (8 %) patients and extremely painful in 57 (5 %)
patients (unpublished data). With the procedural analgesia ad-
ministered using the study product, which preceded the injec-
tion of the local anaesthetic by at least 15min, we considered a
possible reduction to 5 % in the number of patients experienc-
ing a lot of pain or extreme pain. No placebo-controlled study
was conducted to avoid ethical issues and further discomfort
for patients as, being cancer sufferers, they are likely to expe-
rience pain during the course of their illness. The study case-
load was calculated using Simon’s method [20]. Considering
an optimum two-stage design for phase II studies, with an
expected p1–p0 difference of 10 % between the percentage
of patients expressing no or little pain during positioning with
standard local anaesthesia (p0 = 85 %) and that with the ad-
ministration of FBT (p1 = 95%), and setting the probability of
error at α = 0.05 and β = 0.20, the number of patients needed
for stage one was 13. The study was to be ended if fewer than
11 patients with none or mild pain were enrolled in stage one.
Otherwise, the study would have had to continue up to the
enrolment of a total of 65 patients. The efficacy of FBT ad-
ministration was also evaluated by stratifying analysis accord-
ing to the patient’s anxiety state before the procedure.
Results
The studywas conducted fromOctober 2012 till 30 June 2014.
During this period, a total of 513 patients were candidates for
the placement of venous Port as inpatients at this institute. Of
these, 65 (12.6 %) met the study inclusion criteria, gave their
informed consent and were enrolled in the study. The
sociodemographic characteristics of the patients enrolled in
the study are described in Table 1. The majority of cases were
women and the median age was 56 years (range 19–76 years).
A total of 61 (93.9 %) patients perceived none or a little
pain during the procedure. Four patients (6.2 %) reported a lot
of pain (Table 2). No patient reported extreme pain. We found
a statistically significant reduction in pain perception com-
pared to pain assessment of patients not treated with FBT in
the years 2010–2011 (Fisher test p = 0.0018). The rescue
drugs identified for severe pain were never administered as
no patient reported extreme pain (VNRS ≥8) during the pro-
cedure (as reported at the final interview), while those who
experienced a lot of pain (VNRS ≥ 5 < 8) preferred not to take
additional drugs. The pain expectation prior to the interven-
tion and the pre-procedure level of anxiety in patients, mea-
sured using the STAI-Y test, did not significantly affect the
perception of pain. Similarly, there were no statistically sig-
nificant inequalities for gender, age group (<55 or ≥55 years)
or level of education which were investigated using the pre-
liminary interview (Table 2). The side effects of FBT admin-
istration are described in Table 3. Drowsiness was experienced
by 28 patients at T1 (43.1 %) and dropped significantly
(p < 0.01) to 8 patients at T2 (12.5 %). Another commonly
experienced symptom was vertigo, which was present in 19
cases at T1 (29.2 %) and dropped significantly (p < 0.02) to 8
cases (12.5 %) at T2. None of the patients described these
effects as being bothersome. Nausea was present in 6 cases
at T1 (9.2 %) and in 7 cases at T2 (10.9 %). Vomiting was
present in 3 cases at T1 (4.7 %) and in 2 other patients at T2
(7.8 %). No significant change was observed between the















White collar 15 23.1
Blue collar 6 9.2
Retired/housewife 30 46.3
Other 14 21.5
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baseline and subsequent measurements of vital parameters
(blood pressure, peripheral blood O2 saturation by pulse ox-
imetry and respiratory rate) monitored during the procedure
and checked at T1 and T2.
Discussion
Procedural analgesia in adult patients has not been extensively
studied in recent literature. We found only one recent study
performed with oncologic patients which investigated the
safety and efficacy of methoxyflurane for procedural pain of
bone marrow biopsy [21]. One recent study on procedural
sedation and analgesia in the emergency department, where
most procedures concerned fractures and dislocations, report-
ed that midazolam is the most commonly used drug, frequent-
ly in combination with morphine [22]. Central venous
incannulation procedure with placement of a Port is certainly
far less invasive than the reduction of a fracture, and a
midazolam-morphine combination would not have been the
most appropriate analgesia option. Continuous remifentanil
infusion at various doses between 0.025, 0.005 and
0.075 μg/kg/min has been suggested for procedural sedation
and analgesia for Ports and long-term venous catheters
Table 2 Perception of pain during central venous catheter (CVC) positioning
Did you experience pain during the CVC positioning? VNRS (0–10)
Mean (SD)
No pain Little pain A lot of pain
n % n % n %
Overall 33 (50.8) 28 (43.1) 4 (6.2) 2.03 (1.84)
Gender
Male 9 (47.4) 7 (36.8) 3 (15.8) 2.50 (2.28)
Female 24 (52.2) 21 (45.7) 1 (2.2) 1.85 (1.63)
Fisher test; p = 0.14 ANOVA; p = 0.21
Age (years)
<55 14 (46.7) 12 (40.0) 4 (13.3) 2.21 (2.24)
≥55 19 (54.3) 16 (45.7) 0 (0.0) 1.89 (1.45)
Fisher test; p = 0.10 ANOVA; p = 0.49
Education (years)
<9 16 (64.0) 9 (36.0) 0 (0.0) 1.80 (1.58)
9–13 15 (44.1) 15 (44.1) 4 (11.8) 2.18 (2.05)
≥14 2 (33.3) 4 (66.7) 0 (0.0) 2.17 (1.84)
Fisher test; p = 0.23 ANOVA; p = 0.73
Do you expect to experience pain during the CVC positioning?
No pain 4 (80.0) 1 (20.0) 0 (0.0) 1.20 (1.10)
Little pain 24 (54.6) 16 (36.4) 4 (9.1) 1.91 (1.96)
A lot of pain/Extremely painful 5 (31.2) 11 (68.8) 0 (0.0) 2.63 (1.59)
Fisher test; p = 0.14 ANOVA; p = 0.24
Anxiety before CVC positioning (STAI-Y)a
Low 7 (70.0) 3 (30.0) 0 (0.0) 1.10 (1.37)
Medium 24 (46.2) 24 (46.2) 4 (7.7) 2.24 (1.90)
High 2 (66.7) 1 (33.3) 0 (0.0) 1.67 (1.53)
Fisher test; p = 0.63 ANOVA; p = 0.19
aDefined as lower or higher than the mean value ± SD, accounting for gender and age
Table 3 Frequency of side effects following central venous catheter
positioning
Side effects T1 (n = 64) T2 (n = 64) p value
n % n %
Dizziness 28 (43.1) 8 (12.5) <0.01
Nausea 6 (9.2) 7 (10.9) 0.75
Vomiting 3 (4.7) 5 (7.8) 0.47
Vertigo 19 (29.2) 8 (12.5) 0.02
Other 4 (6.2) 3 (4.7) 0.71
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positioning and removal [23]. The drug has been proven to be
an efficacious analgesic at all three doses, but is burdened by
the risk of excessive sedation and respiratory and cardiovas-
cular depression at higher doses. Continuous remifentanil in-
fusion however requires the identification of a venous access
prior to the procedure and close vital parameter monitoring. A
study on procedural sedation and analgesia with fentanyl at a
dose of 2 μg/kg versus placebo for central venous
incannulation showed a significant level of pain reduction.
[14]. This study considered short-term catheters, which are
less invasive in terms of placement technique; however, the
procedures are conducted using anatomical markers for vein
identification.
This usually involves greater difficulty and a higher num-
ber of skin and vein punctures, with a higher failure rate than
the ultrasound-guided incannulation technique we used. The
precision and speed of ultrasound-guided puncture can be
considered as a first factor for reducing patient discomfort
and anxiety. Indeed, the ultrasound-guided technique allowed
us to complete the procedure with little or no pain in 87 % of
the cases treated with anaesthesia by local infiltration alone
prior to the start of the study. We believed that such a high
number of procedures with low patient discomfort could be
improved, by identifying a simple-to-administer pre-
medication that does not require venipuncture and that is safe
for the patient. The main feature of procedural analgesia for
Port positioning is conscious sedation since it allows patient
collaboration in the control of breathing, apnoea and the
Valsalva manoeuvre. FBT pre-medication ensures this. The
percentage of patients with no or little procedural pain was
around 93.9 % when local anaesthesia was associated with
pre-medication with FBT. FBT is not currently approved for
administration in opioid-naïve patients; however, its safety
proved to be very high, without alterations in baseline param-
eters throughout the observation period of 4 h subsequent to
administration. Amongst the various side effects, dizziness
presented in a significant number of patients at T1 (43.1 %)
but was never considered bothersome or unpleasant for the
patient and was significantly reduced at T2 (12.5 %), corre-
sponding to the 4 h following the end of the pharmacological
effect of FBT. Vertigo, the second most common side effect,
was also judged not to be bothersome or uncomfortable. Nau-
sea and vomiting were less common but more uncomfortable,
and unlike other side effects, they increased, albeit in a non-
significant manner, at T2 compared to T1. In connection with
this, it is important to note that all patients complaining of
nausea following anaesthesia had been pre-medicated on the
ward with 10 mg of oral metoclopramide at the discretion of
the anaesthesiologist who collected the consent. These pa-
tients did not present nausea and vomiting at T1 and T2
checks, which suggests that antiemetic pre-medication should
always accompany the use of FBTas a procedural analgesic in
opioid-naïve patients. The pre-procedure anxiety and pain
expectation study showed that they did not have any influence
on the perception of pain itself and they are not, therefore,
useful, in our opinion, for selecting potential patients at risk
of procedural pain.
Conclusions
The significant improvement in the number of patients
experiencing no or little pain in procedural analgesia for cen-
tral venous incannulation and the placement of a Port per-
formed with FBT pre-medication and local anaesthesia infil-
tration compared to the standard technique performed with
local infiltration anaesthesia alone, that was the technical stan-
dard of our procedure performed in the years prior to the study,
was accompanied by a lower number of non-severe side ef-
fects. We believe that this suggests using FBT as a valid,
practical and safe method of procedural analgesia. It is never-
theless necessary to perform further studies taking into ac-
count the need for standard antiemetic pre-medication to min-
imise the incidence of nausea and vomiting that appear to be
limiting factors to the performance of procedural analgesia
with FBT in opioid-naïve patients.
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